Company

PainReform Ltd.

Headquarters: Herzliya, Israel

Employees: 1

CEO: Mr. Ilan Hadar M.B.A., MBA

NASDAQ: PRFX -2.91%

Market Cap

$2.7 Million

USD as of Jan. 1, 2025

Market Cap History

PainReform Ltd. Categories

Israel Healthcare Drug Manufacturers—Specialty & Generic
Israel Healthcare Israel Drug Manufacturers—Specialty & Generic

PainReform Ltd. market capitalization over time

Evolution of PainReform Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PainReform Ltd.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
Zoetis Inc. $75.33 B
MERCK Kommanditgesellschaft auf Aktien $65.17 B
Haleon plc $42.16 B
Takeda Pharmaceutical Company Limited $41.47 B
Teva Pharmaceutical Industries Limited $18.95 B
Sector:
Company Market Cap (USD)
Lilly $689.42 B
Novo Nordisk $622.07 B
UnitedHealth Group $487.54 B
Johnson & Johnson $353.05 B
AbbVie $301.60 B

Detailed Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Stocks & Indices

PainReform Ltd. has the following listings and related stock indices.


Stock: NASDAQ: PRFX wb_incandescent

Details

Headquarters:

60C Medinat Hayehudim Street

Herzliya, 4676670

Israel

Phone: 972 9 960 1901

Fax: 972 9 954 2266